Nanoparticles for monoclonal antibody delivery
View Patent ↗The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent of monoclonal antibody. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.
1. A pharmaceutical composition of nanoparticles for oral administration in a patient, said nanoparticles comprising a shell portion of biodegradable chitosan that is positively charged, a core portion of negatively charged substrate of polyglutamic acid (PGA) that is neutralized with a portion of positively charged chitosan, and a monoclonal antibody loaded within said nanoparticles, wherein said nanoparticles further comprise at least one paracellular transport enhancer.
2. The pharmaceutical composition of claim 1 , wherein said PGA is γ-PGA.
3. The pharmaceutical composition of claim 1 , wherein a surface of said nanoparticles is characterized with a positive surface charge.
4. The pharmaceutical composition of claim 1 , wherein said nanoparticles have an average diameter from about 50 nm to about 500 nm.
5. The pharmaceutical composition of claim 1 , wherein said nanoparticles have a surface charge from about +15 mV to about +50 mV.
6. The pharmaceutical composition of claim 1 , wherein said nanoparticles are encapsulated in a capsule.
7. The pharmaceutical composition of claim 6 , wherein said capsule is treated with an enteric coating.
8. The pharmaceutical composition of claim 1 , wherein said monoclonal antibody is conjugated to said negatively charged substrate.
9. The pharmaceutical composition of claim 1 , wherein said monoclonal antibody binds only to cancer cells in the patient.
10. The pharmaceutical composition of claim 1 , wherein the monoclonal antibody suppress the immune system of the patient.
11. The pharmaceutical composition of claim 1 , wherein the monoclonal antibody kills or inhibits malignant cells in the patient.
12. The pharmaceutical composition of claim 1 , wherein said nanoparticles are formed via a simple and mild ionic-gelation method.
13. The pharmaceutical composition of claim 1 , wherein said paracellular transport enhancer is a Ca 2+ chelator.